PCM
INSY

Prelude Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Prelude Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-300
Closed -$3K – 1895
2017
Q3 		$3K Buy
+300
New +$3.1K ﹤0.01% 1550

Other funds holding INSY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RCM
Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Prelude Capital Management's INSY Position: Q1 2019 in Review

Prelude Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 486 shares — an estimated $2K sold.

Prelude Capital Management first reported a position in INSY in Q2 2014 and held it in 16 quarters. The position peaked at $156K in Q2 2014. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

  • Prelude Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Prelude Capital Management sold 486 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $2K.
  • Prelude Capital Management first reported a position in Insys Therapeutics, Inc. in Q2 2014 and held it in 16 quarters.
  • Prelude Capital Management's Insys Therapeutics, Inc. position peaked at $156K in Q2 2014.
  • 98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on Prelude Capital Management's 13F filing for Q1 2019, filed 15 May 2019.